부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
Company news | Contera Pharma, a subsidiary of Bukwang Pharmaceutical, att..
- 3 million dollars invested by Medici Investment- European Clinical phase 2 stu..
2019.07.10
R&D news | University of Dundee partners with Bukwang Pharmaceutical Co..
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-milli..
2019.07.03
R&D news | BNO BIO, a joint company by Bukwang and OCI, invests in a b..
- BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture- The first ..
2019.06.28
R&D news | Bukwang Announced commencement of Phase 2 Clinical Study of..
- to be completed within 2 yearsBukwang Pharmaceutical (“Bukwang”) announced tod..
2019.06.26
R&D news | Bukwang Announces Completion of MLR-1023’s Phase 2b clinica..
- Fast speed of study progression, expecting results in January next yearMLR-102..
2018.12.17
R&D news | Bukwang Announces completion of dosing of MLR-1023’s phase 2..
Bukwang announced that it has completed the clinical trials of MLR-1023, a new d..
2018.11.29
6
7
8
9
10